The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rheumatoid Arthritis Medicine Market Research Report 2025
Synopsis
Rheumatoid Arthritis is an autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. The disease may last from months to a lifetime, and symptoms may improve and worsen over time.
Global Rheumatoid Arthritis Medicine market is projected to reach US$ 485.7 million in 2029, increasing from US$ 358 million in 2022, with the CAGR of 4.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rheumatoid Arthritis Medicine market research.
Key manufacturers engaged in the Rheumatoid Arthritis Medicine industry include AbbVie Inc, Hoffman-La Roche AG, Amgen Inc, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, UCB Biosciences Inc, Mitsubishi Tanabe Pharma Corp and Biogen Inc, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rheumatoid Arthritis Medicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rheumatoid Arthritis Medicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rheumatoid Arthritis Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie Inc
Hoffman-La Roche AG
Amgen Inc
Pfizer Inc
Bristol-Myers Squibb Co
Johnson & Johnson
UCB Biosciences Inc
Mitsubishi Tanabe Pharma Corp
Biogen Inc
Merck & Co
Haute Autorité de Santé
Segment by Type
Prescription Drugs
OTC Drugs
Segment by Application
Hospital
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rheumatoid Arthritis Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Rheumatoid Arthritis is an autoimmune disease that causes pain, swelling, and stiffness in the joints, and may cause severe joint damage, loss of function, and disability. The disease may last from months to a lifetime, and symptoms may improve and worsen over time.
Global Rheumatoid Arthritis Medicine market is projected to reach US$ 485.7 million in 2029, increasing from US$ 358 million in 2022, with the CAGR of 4.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rheumatoid Arthritis Medicine market research.
Key manufacturers engaged in the Rheumatoid Arthritis Medicine industry include AbbVie Inc, Hoffman-La Roche AG, Amgen Inc, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, UCB Biosciences Inc, Mitsubishi Tanabe Pharma Corp and Biogen Inc, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rheumatoid Arthritis Medicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rheumatoid Arthritis Medicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rheumatoid Arthritis Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie Inc
Hoffman-La Roche AG
Amgen Inc
Pfizer Inc
Bristol-Myers Squibb Co
Johnson & Johnson
UCB Biosciences Inc
Mitsubishi Tanabe Pharma Corp
Biogen Inc
Merck & Co
Haute Autorité de Santé
Segment by Type
Prescription Drugs
OTC Drugs
Segment by Application
Hospital
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rheumatoid Arthritis Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Rheumatoid Arthritis Medicine Market Overview
1.1 Product Overview and Scope of Rheumatoid Arthritis Medicine
1.2 Rheumatoid Arthritis Medicine Segment by Type
1.2.1 Global Rheumatoid Arthritis Medicine Market Value Comparison by Type (2023-2029)
1.2.2 Prescription Drugs
1.2.3 OTC Drugs
1.3 Rheumatoid Arthritis Medicine Segment by Application
1.3.1 Global Rheumatoid Arthritis Medicine Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Rheumatoid Arthritis Medicine Market Size Estimates and Forecasts
1.4.1 Global Rheumatoid Arthritis Medicine Revenue 2018-2029
1.4.2 Global Rheumatoid Arthritis Medicine Sales 2018-2029
1.4.3 Global Rheumatoid Arthritis Medicine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Rheumatoid Arthritis Medicine Market Competition by Manufacturers
2.1 Global Rheumatoid Arthritis Medicine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Rheumatoid Arthritis Medicine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Rheumatoid Arthritis Medicine Average Price by Manufacturers (2018-2023)
2.4 Global Rheumatoid Arthritis Medicine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Rheumatoid Arthritis Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rheumatoid Arthritis Medicine, Product Type & Application
2.7 Rheumatoid Arthritis Medicine Market Competitive Situation and Trends
2.7.1 Rheumatoid Arthritis Medicine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rheumatoid Arthritis Medicine Players Market Share by Revenue
2.7.3 Global Rheumatoid Arthritis Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rheumatoid Arthritis Medicine Retrospective Market Scenario by Region
3.1 Global Rheumatoid Arthritis Medicine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Rheumatoid Arthritis Medicine Global Rheumatoid Arthritis Medicine Sales by Region: 2018-2029
3.2.1 Global Rheumatoid Arthritis Medicine Sales by Region: 2018-2023
3.2.2 Global Rheumatoid Arthritis Medicine Sales by Region: 2024-2029
3.3 Global Rheumatoid Arthritis Medicine Global Rheumatoid Arthritis Medicine Revenue by Region: 2018-2029
3.3.1 Global Rheumatoid Arthritis Medicine Revenue by Region: 2018-2023
3.3.2 Global Rheumatoid Arthritis Medicine Revenue by Region: 2024-2029
3.4 North America Rheumatoid Arthritis Medicine Market Facts & Figures by Country
3.4.1 North America Rheumatoid Arthritis Medicine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Rheumatoid Arthritis Medicine Sales by Country (2018-2029)
3.4.3 North America Rheumatoid Arthritis Medicine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rheumatoid Arthritis Medicine Market Facts & Figures by Country
3.5.1 Europe Rheumatoid Arthritis Medicine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Rheumatoid Arthritis Medicine Sales by Country (2018-2029)
3.5.3 Europe Rheumatoid Arthritis Medicine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rheumatoid Arthritis Medicine Market Facts & Figures by Country
3.6.1 Asia Pacific Rheumatoid Arthritis Medicine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Rheumatoid Arthritis Medicine Sales by Country (2018-2029)
3.6.3 Asia Pacific Rheumatoid Arthritis Medicine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Rheumatoid Arthritis Medicine Market Facts & Figures by Country
3.7.1 Latin America Rheumatoid Arthritis Medicine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Rheumatoid Arthritis Medicine Sales by Country (2018-2029)
3.7.3 Latin America Rheumatoid Arthritis Medicine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rheumatoid Arthritis Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Rheumatoid Arthritis Medicine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Rheumatoid Arthritis Medicine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Rheumatoid Arthritis Medicine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rheumatoid Arthritis Medicine Sales by Type (2018-2029)
4.1.1 Global Rheumatoid Arthritis Medicine Sales by Type (2018-2023)
4.1.2 Global Rheumatoid Arthritis Medicine Sales by Type (2024-2029)
4.1.3 Global Rheumatoid Arthritis Medicine Sales Market Share by Type (2018-2029)
4.2 Global Rheumatoid Arthritis Medicine Revenue by Type (2018-2029)
4.2.1 Global Rheumatoid Arthritis Medicine Revenue by Type (2018-2023)
4.2.2 Global Rheumatoid Arthritis Medicine Revenue by Type (2024-2029)
4.2.3 Global Rheumatoid Arthritis Medicine Revenue Market Share by Type (2018-2029)
4.3 Global Rheumatoid Arthritis Medicine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Rheumatoid Arthritis Medicine Sales by Application (2018-2029)
5.1.1 Global Rheumatoid Arthritis Medicine Sales by Application (2018-2023)
5.1.2 Global Rheumatoid Arthritis Medicine Sales by Application (2024-2029)
5.1.3 Global Rheumatoid Arthritis Medicine Sales Market Share by Application (2018-2029)
5.2 Global Rheumatoid Arthritis Medicine Revenue by Application (2018-2029)
5.2.1 Global Rheumatoid Arthritis Medicine Revenue by Application (2018-2023)
5.2.2 Global Rheumatoid Arthritis Medicine Revenue by Application (2024-2029)
5.2.3 Global Rheumatoid Arthritis Medicine Revenue Market Share by Application (2018-2029)
5.3 Global Rheumatoid Arthritis Medicine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie Inc
6.1.1 AbbVie Inc Corporation Information
6.1.2 AbbVie Inc Description and Business Overview
6.1.3 AbbVie Inc Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Inc Rheumatoid Arthritis Medicine Product Portfolio
6.1.5 AbbVie Inc Recent Developments/Updates
6.2 Hoffman-La Roche AG
6.2.1 Hoffman-La Roche AG Corporation Information
6.2.2 Hoffman-La Roche AG Description and Business Overview
6.2.3 Hoffman-La Roche AG Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Hoffman-La Roche AG Rheumatoid Arthritis Medicine Product Portfolio
6.2.5 Hoffman-La Roche AG Recent Developments/Updates
6.3 Amgen Inc
6.3.1 Amgen Inc Corporation Information
6.3.2 Amgen Inc Description and Business Overview
6.3.3 Amgen Inc Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Amgen Inc Rheumatoid Arthritis Medicine Product Portfolio
6.3.5 Amgen Inc Recent Developments/Updates
6.4 Pfizer Inc
6.4.1 Pfizer Inc Corporation Information
6.4.2 Pfizer Inc Description and Business Overview
6.4.3 Pfizer Inc Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Inc Rheumatoid Arthritis Medicine Product Portfolio
6.4.5 Pfizer Inc Recent Developments/Updates
6.5 Bristol-Myers Squibb Co
6.5.1 Bristol-Myers Squibb Co Corporation Information
6.5.2 Bristol-Myers Squibb Co Description and Business Overview
6.5.3 Bristol-Myers Squibb Co Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Co Rheumatoid Arthritis Medicine Product Portfolio
6.5.5 Bristol-Myers Squibb Co Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Johnson & Johnson Rheumatoid Arthritis Medicine Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 UCB Biosciences Inc
6.6.1 UCB Biosciences Inc Corporation Information
6.6.2 UCB Biosciences Inc Description and Business Overview
6.6.3 UCB Biosciences Inc Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 UCB Biosciences Inc Rheumatoid Arthritis Medicine Product Portfolio
6.7.5 UCB Biosciences Inc Recent Developments/Updates
6.8 Mitsubishi Tanabe Pharma Corp
6.8.1 Mitsubishi Tanabe Pharma Corp Corporation Information
6.8.2 Mitsubishi Tanabe Pharma Corp Description and Business Overview
6.8.3 Mitsubishi Tanabe Pharma Corp Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Mitsubishi Tanabe Pharma Corp Rheumatoid Arthritis Medicine Product Portfolio
6.8.5 Mitsubishi Tanabe Pharma Corp Recent Developments/Updates
6.9 Biogen Inc
6.9.1 Biogen Inc Corporation Information
6.9.2 Biogen Inc Description and Business Overview
6.9.3 Biogen Inc Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Biogen Inc Rheumatoid Arthritis Medicine Product Portfolio
6.9.5 Biogen Inc Recent Developments/Updates
6.10 Merck & Co
6.10.1 Merck & Co Corporation Information
6.10.2 Merck & Co Description and Business Overview
6.10.3 Merck & Co Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Merck & Co Rheumatoid Arthritis Medicine Product Portfolio
6.10.5 Merck & Co Recent Developments/Updates
6.11 Haute Autorité de Santé
6.11.1 Haute Autorité de Santé Corporation Information
6.11.2 Haute Autorité de Santé Rheumatoid Arthritis Medicine Description and Business Overview
6.11.3 Haute Autorité de Santé Rheumatoid Arthritis Medicine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Haute Autorité de Santé Rheumatoid Arthritis Medicine Product Portfolio
6.11.5 Haute Autorité de Santé Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rheumatoid Arthritis Medicine Industry Chain Analysis
7.2 Rheumatoid Arthritis Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rheumatoid Arthritis Medicine Production Mode & Process
7.4 Rheumatoid Arthritis Medicine Sales and Marketing
7.4.1 Rheumatoid Arthritis Medicine Sales Channels
7.4.2 Rheumatoid Arthritis Medicine Distributors
7.5 Rheumatoid Arthritis Medicine Customers
8 Rheumatoid Arthritis Medicine Market Dynamics
8.1 Rheumatoid Arthritis Medicine Industry Trends
8.2 Rheumatoid Arthritis Medicine Market Drivers
8.3 Rheumatoid Arthritis Medicine Market Challenges
8.4 Rheumatoid Arthritis Medicine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
